IL33 and pulmonary fibrosis: To investigate whether extracellular IL-33 has pro-fibrotic effects in a complex biological system, an inhibitor of IL-33 signalling, ST2-Fc fusion protein [33, 34], was delivered during the fibrotic phase of the BLM model of pulmonary fibrosis (Fig. 4A).